In sedentary T2D patients, 12-weeks AIT individualized by TRIMPi method improved AS to a greater extent than usual recommendation on physical activity, whilst exerting comparable effects on exercise capacity, glycemic control and body weight. Further researches are needed to ascertain durability of these effects.

Background: SGLT2i proved efficacy in reducing cardiovascular morbidity and mortality in T2D patients at high cardiovascular risk. Aims: In real-word setting, we prospectively evaluated long-term effects of Dapagliflozin (DAPA) on left diastolic ventricular function (LDVF) and vascular reactivity in T2D patients without known cardiovascular disease. Population, Study and Methods: 13 patients (9 male, 57± 8 years, BMI 29.6± 3.6, HbA1c 8.9±1.2%, years of T2D 9±5, fasting glucose 185±51 mg/dl) initiated DAPA 10 mg daily as add-on to metformin. Following data were collected at baseline (T0), after 12 weeks (T1) and 52 weeks (T2) of treatment: blood pressure, anthropometrics, fasting glucose, HbA1c, eGFR and lipids. Ratio of the early (E) to late (A) ventricular filling velocities (E/A) was used to evaluate LDVF. Arterial stiffness was evaluated by Pulse Wave Velocity (PWV) and Augmentation Index (AIxHR75) with radial approach (SphygmoCor System). Endothelial function was assessed by non-invasive flow mediated dilatation (FMD). Results: We observed significant percent variation in HbA1c (T1 vs. T0 -17.9%, p=0.001; T2 vs. T0 -17.4%, p=0.01), fasting glucose (T1 vs. T0 -25.9%, p=0.002, T2 vs. T0 -31.8%, p=0.005) systolic blood pressure (T1 vs. T0 -6.7%, p=0.03; T2 vs. T0 -10.2% p=0.02) and BMI (T1 vs. T0 -3.3%, p=0.001; T2 vs. T0 -3%, p=0.02). Significant improvements from baseline of E/A ratio (T1 vs. T0 +15%, p=0.03; T2 vs. T0 +27.5%, p=0.003) and brachial FMD (T1 vs. T0 +50.7%, p=0.02; T2 vs. T0 +39.4%, p=0.04) were also seen. No significant changes in eGFR, lipids and arterial stiffness measures were seen. Conclusions: Intensification of treatment with DAPA 10 mg was accompanied by significant improvements in LVDF and endothelial-dependent vasodilation measures, which persist after 52 weeks of treatment. These preliminary observational results shed light on potential mechanisms responsible for cardiovascular protection with SGLT2i in T2D patients, even in absence of overt cardiovascular disease. Disclosure I. D'ippolito: None. E. De Carli: None. A. Andreadi: None. M. Romano: None. A. Galli: None. A. Capria: None. M. Massaro: None. P. Sbraccia: None. D. Della-Morte: None. A. Bellia: None. D. Lauro: None. Funding University of Rome

Background Inflammatory bowel disease (IBD) are complex chronic disabling disease with variable disease activity. Physicians’ and patients’ perception of disease burden may vary considerably. The use of eHealth tools is a useful technique to monitor disease burden, but physicians- and patients-reported disease measurement do not overlap completely. Aim of this study was to perspectively explore agreement for rating disease activity and impact between patients, senior (consultants) and junior (residents) physicians. Methods Using a tele-monitoring platform (IBD Tool), 508 consecutive IBD patients filled disease activity (Harvey Bradshaw Index, HBI, for Crohn’s and Patient Simple Clinical Colitis Activity Index, P-SCCAI, as appropriate) and disease impact (Pictorial Representation of Illness and Self-Measure, PRISM) validated questionnaires at the time of outpatient visits. At the same timepoint also senior and junior physicians filled the same activity (HBI and Clinician SCCA, C-SCCAI) and impact (PRISM) questionnaires. Agreement between patients’ and physicians’ scores was analysed with intraclass and concordance correlation coefficients and Spearman’s rank correlation coefficient. Results A total of, 629 filled questionnaires regarding, 508 patients was available for analysis. Crohn’s patients were, 52%, and females were, 50%, median age of patients was, 44 years, and their median age at diagnosis was, 28 years, while median disease duration was, 12 years; overall, 39% of patients underwent surgery before being enrolled. Agreement for different scores among patients, senior and junior physicians was always significant and details are reported in Table, 1. Table, 1. Agreement among patients, senior and junior physicians for HBI, SCCAI and PRISM. A closer inverse relationship between activity indices and PRISM was found in physicians’ scores, while it was looser in patients’ scores. Senior physicians’ agreement was -0.774 and -0.793 for HBI and C-SCCAI, respectively, to PRISM (p<0.0001); Junior physicians’ agreement was -0.745 and -0.753 for HBI and C-SCCAI, respectively, to PRISM (p<0.0001); patients’ agreement was -0.414 and -0.498 for HBI and C-SCCAI, respectively, to PRISM (p<0.0001). Conclusion Agreement of patients’ and physicians’ scoring of disease activity on a tele-monitoring platform is good and significant, and it is optimal between junior and senior doctors. According to published data, physicians’ and patients’ agreement regarding the perception of disease impact on patients’ lives (measured with PRIMS) is slightly worse, although still significant, while it is good comparing junior and senior physicians’ rates. When exploring relationships between PRISM and disease activity scores it is good for physicians, and only average for patients.

Background Tele-monitoring and eHealth tools are useful to monitor disease burden and activity in inflammatory bowel disease (IBD). We developed a web-based tele-monitoring platform (IBD Tool), in order to monitor granularly disease activity and impact on patients’ lives. Aim of this abstract is to report preliminary data on IBD Tool effectiveness. Methods Consecutive IBD patients were offered the access to the tele-monitoring platform (IBD Tool) as a part of an ongoing investigator-initiated observational study, overall 677 patients were enrolled between February and November 2021. Validated questionnaires administered on the platform captured disease activity [Harvey Bradshaw Index (HBI), Simple Clinical Colitis Activity Index (SCCAI), Monitor IBD At Home Questionnaire for Crohn’s disease (CD) or for ulcerative colitis (UC): MIAH-CD or MIAH-UC] and disease burden and quality of life. Patients were randomized 1:1 to standard of care (only activity questionnaires required every 3-months) and telemedicine (activity questionnaires required monthly, remaining questionnaires every 3-months). Results Out of 678 patients enrolled, 585 (87%) are active on the platform and filled overall 14,297 questionnaires during an average follow-up of 9.8 months, the mean number of questionnaires filled/patient was 24.9. Characteristics of the patient enrolled in the study are presented in Table 1. Table 1. Characteristics of patients enrolled on the IBD Tool tele-monitoring platform and questionnaires filled Among the 320 cases with 2 or more observations in the IBD Tool platform, it was possible to analyse disease activity variation (summarized as constant, amelioration, or worsening) according to SCCAI or HBI changes ±2 points, results are detailed in Table 2. Table 2. Charateristics of patients constant, ameliorating or worsening in time. Conclusion Patients’ persistence in the tele-monitoring system is adequate; the systems offer granular and precise multidimensional evaluation of IBD patients.